ProQR Therapeutics (NASDAQ:PRQR) Announces Earnings Results

ProQR Therapeutics (NASDAQ:PRQR) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.15) EPS for the quarter, hitting the consensus estimate of ($0.15), FiscalAI reports. ProQR Therapeutics had a negative net margin of 255.83% and a negative return on equity of 65.89%. The firm had revenue of $2.35 million for the quarter, compared to the consensus estimate of $5.19 million.

ProQR Therapeutics Stock Down 1.5%

Shares of NASDAQ:PRQR traded down $0.02 on Tuesday, hitting $1.59. The company had a trading volume of 47,243 shares, compared to its average volume of 521,290. The firm’s 50-day simple moving average is $1.69 and its two-hundred day simple moving average is $1.89. The firm has a market capitalization of $167.10 million, a price-to-earnings ratio of -3.45 and a beta of 0.08. ProQR Therapeutics has a 1 year low of $1.33 and a 1 year high of $3.10.

Institutional Trading of ProQR Therapeutics

Several large investors have recently bought and sold shares of the company. Osaic Holdings Inc. raised its position in shares of ProQR Therapeutics by 59.6% in the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 4,500 shares in the last quarter. Persistent Asset Partners Ltd raised its holdings in ProQR Therapeutics by 24.5% in the fourth quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock worth $91,000 after purchasing an additional 8,874 shares in the last quarter. Diadema Partners LP lifted its position in ProQR Therapeutics by 6.2% during the fourth quarter. Diadema Partners LP now owns 167,532 shares of the biopharmaceutical company’s stock valued at $338,000 after buying an additional 9,838 shares during the period. Raymond James Financial Inc. lifted its position in ProQR Therapeutics by 15.2% during the 3rd quarter. Raymond James Financial Inc. now owns 110,270 shares of the biopharmaceutical company’s stock valued at $235,000 after acquiring an additional 14,549 shares during the period. Finally, Guggenheim Capital LLC purchased a new position in shares of ProQR Therapeutics during the fourth quarter valued at approximately $35,000. 32.65% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on PRQR shares. Wall Street Zen upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, March 14th. Chardan Capital reissued a “buy” rating and set a $4.00 price objective on shares of ProQR Therapeutics in a research note on Thursday, April 9th. Citigroup reiterated a “market outperform” rating on shares of ProQR Therapeutics in a report on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Tuesday, April 21st. Finally, Oppenheimer began coverage on shares of ProQR Therapeutics in a report on Thursday, March 12th. They set an “outperform” rating and a $9.00 target price for the company. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $7.25.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.